Investigation on a Topical Cosmetic Pain Lotion (Egyfil) for Stiffness and Pain Relief

26 male and female patients, ranging from 24 to 78 years old, will receive Egyfil Pain Lotion given for the treatment of pain and stiffness over a three-days period. The primary objective of the study is to evaluate the clinical performance of the lotion in providing relief from stiffness, reduced mobility, and muscle tension pain.

Inclusion criteria

• signed participants informed consent form (ICF);
• male or Female, aged > 18 years at the time of the signature of ICF;
• 3 to 10 rating according to the Numerical Rating Scale (NRS), applied in participants with muscle tension pain;
• willing to follow all study procedures;
• willing to follow indications.

Exclusion criteria

• use of analgesics within the 24 hours prior to V1;
• damaged skin in the area of treatment;
• infective or prior inflammatory processes near the area of treatment;
• ongoing cutaneous allergies;
• serious and chronical pathological skin conditions (i.e., rosacea, psoriasis, vitiligo) including diagnosticated cancer with/without ongoing antitumor therapy;
• allergy to lotion components (aqua (water), glycerin, caprylic/capric triglyceride, aloe barbadensis leaf juice powder, simmondsia chinensis seed oil (simmondsia chinensis (jojoba) seed oil), phenoxyethanol, ammonium acryloyldimethyltaurate/vp copolymer, carbomer, tocopheryl acetate, tocopherol, benzoic acid, sodium hydroxide, sodium hyaluronate, dehydroacetic acid, ethylhexylglycerin, butyrospermum parkii butter (butyrospermum parkii (shea butter)), sorbitol, SH-polypeptide 6; SH-oligopeptide-1
• immune system illnesses;
• uncontrolled systemic diseases;
• known drug and/or alcohol abuse;
• mental incapacity that precludes adequate understanding or cooperation;
• participation in another investigational study.